Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis

PHASE4TerminatedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 26, 2022

Primary Completion Date

February 15, 2024

Study Completion Date

February 15, 2024

Conditions
Atopic Dermatitis
Interventions
DRUG

Crisaborole 2%

The adult caregiver will apply a thin layer of Crisaborole 2% topically on their child participant twice a day for 2 weeks.

DRUG

Vehicle treatment

The adult caregiver will apply a thin layer of the vehicle treatment topically on their child participant twice a day for 2 weeks. The vehicle treatment is made of excipients of crisaborole ointment (non-medicated ointment).

DEVICE

Accelerometry device for children

Children participants will wear two wrist worn (or wrist worn AND ankle worn for 3 months up to \<2 years) accelerometry devices. Devices will be optional for child participants who have active AD on location of device placement, with a minimum of at least one wrist device needed for enrollment.

DEVICE

Accelerometry device for adult caregivers

Adult caregiver participants will wear two accelerometry devices (one on each wrist) and complete daily assessments related to scratching, sleeping habits, pain, AD severity, quality of life, and device comfort questionnaires.

Trial Locations (1)

02118

BU CAMed Laboratory for Human Neurobiology, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Boston University

OTHER

NCT05200403 - Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis | Biotech Hunter | Biotech Hunter